Intra-Cellular Therapies Cleared for Quotation on

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
Intra-Cellular Therapies Cleared for Quotation on OTCQB

NEW YORK , Dec. 19, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced that its common stock has been approved for quotation on the OTC Markets – OTCQB tier (OTCQB) under the symbol "ITCI", and is expected to begin trading on December 20, 2013 .

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS").  The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia and other neuropsychiatric and neurological disorders.  In December 2013 , the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia.  In this study, ITI-007 met the trial's pre-specified primary endpoint, improving symptoms associated with schizophrenia as measured by a statistically significant and clinically meaningful decrease in the Positive and Negative Syndrome Scale (PANSS) total score.  The trial also met key secondary outcome measures related to efficacy on PANSS subscales and safety. In the Phase II trial, ITI-007 exhibited a differentiating response profile across a broad range of symptoms that we believe is consistent with improvements in social functioning deficits.

The Company is also developing other drug candidates.  In February 2011 , the Company entered into a collaboration with the Takeda Pharmaceutical Company to develop certain phosphodiesterase 1 (PDE1) inhibitors for the treatment of cognitive deficits in schizophrenia and other CNS disorders.  In February 2013 , the Company announced the successful completion of a Phase I single rising dose study of the lead molecule in the ITI/Takeda collaboration, ITI-214.  The Company has additional programs in the areas of Parkinson's disease, Alzheimer's disease, depression and cardiovascular disease.

Forward-looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the expected timing of the commencement of trading on the OTCQB of our common stock, the results of our Phase 2 clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia, and our research and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to the following: our current and planned clinical trials for ITI-007 and our other product candidates may not be successful or may take longer and be more costly than anticipated;  product candidates that appeared promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our reliance on collaborative partners and other third-parties for further clinical trials, development and commercialization of our product candidates; the costs associated with our research, development and other activities may exceed those that we estimate; the conduct and results of preclinical and clinical studies of our product candidates may pose challenges for the ongoing development of our product candidates; we may experience difficulties or delays in obtaining regulatory approvals to market products; we may experience difficulties in raising additional capital to pursue our operating plans, which could materially adversely affect our ability to continue as an enterprise; our intellectual property may not provide the protection we require, and we may be subject to third-party intellectual property claims; we may fail to comply with extensive regulatory requirements; we may experience safety issues with ITI-007 or other product candidates that render such potential products of limited value; as well as risks related to key employees, markets, economic conditions, health care reform, prices and reimbursement rates and the other risk factors discussed under the heading "Risk Factors" contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on October 31, 2013 , as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. We do not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in our expectations, except as required by law.

CONTACT:
Allen A. Fienberg , Ph.D.
Vice President
Business Development of Intra-Cellular Therapies, Inc.
+1-212-923-3344

Burns McClellan, Inc.
Lisa Burns / Angeli Kolhatkar (Investors)
Justin Jackson (Media)
jjackson@burnsmc.com
Phone +1 (212) 213-0006

SOURCE Intra-Cellular Therapies, Inc.


Source: PR Newswire (December 19, 2013 - 7:25 PM EST)

News by QuoteMedia
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 95

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 94

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading

Top 5 Most Recently Viewed Articles

APh ePower's 2025 R&D Achievement: Transforming Elevator Energy

Updated Category News Views 178

APh ePower's Remarkable Innovation Award The leader in aluminum battery technology is not only setting standards for efficiency but is also making strides in sustainability. Recently, APh ePower was honored with the prestigious 2025 R&D 100 Award for its groundbreaking Elevator Regenerative Power System (ERPS). This award highlights the company's efforts in redefining...

Continue Reading
Butterfly Completes $300 Million Loan for Milk Specialties Growth

Updated Category News Views 349

Butterfly Completes Major Dividend Recapitalization Butterfly, a well-known private equity firm based in Los Angeles, has made a significant move in the food industry by securing a substantial $300 million second lien term loan facility. This funding is intended to support Milk Specialties Global, an important portfolio company recognized for its innovative methods in...

Continue Reading
Rezolve Ai Enhances BRAiN Assistant for Optimal User Engagement

Updated Category News Views 73

Rezolve Ai Introduces Key Updates to BRAiN Assistant Rezolve Ai (Nasdaq: RZLV) has made a bold move in the realm of AI technology with a substantial update to its BRAiN Assistant. This upgraded platform is designed to significantly enhance user experience and response accuracy, reinforcing the company's dedication to harnessing innovative technology for superior AI-driven...

Continue Reading
Minesto Teams Up to Unlock Tidal Power in Maldives

Updated Category News Views 270

The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...

Continue Reading
Promising New Insights on Dual Masked T-Cell Engagers from Vir

Updated Category News Views 216

Encouraging Developments in Cancer Treatment by Vir Biotechnology Vir Biotechnology, Inc. (NASDAQ: VIR) has recently shared commendable initial Phase 1 data regarding their innovative dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500. These breakthroughs target challenging forms of cancer, notably HER2-expressing solid tumors and metastatic castration-resistant...

Continue Reading